Recombinant Mouse IFN-alpha 2/IFNA2 Protein, CF

Recombinant Mouse IFN-alpha 2/IFNA2 (Catalog # 10149-IF)suppresses viral activity on L-929 mouse fibroblast cells infected withencephalomyocarditis (EMC) virus. The ED50 for this effect is 20-200 pg/mL.

2 μg/lane of Recombinant Mouse IFN-alpha 2/IFNA2 (Catalog # 10149-IF) was resolved withSDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized byCoomassie® Blue staining, showing bands at 18-22 kDa.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse IFN-alpha 2/IFNA2 Protein, CF Summary

• Details of Functionality: Measured in an anti-viral assay using L‑929 mouse fibroblast cells infected with encephalomyocarditis (EMC) virus. Vogel, S.N. et al. (1982) Infect. Immunol. 38:681. The ED₅₀ for this effect is 20-200 pg/mL.
• Source: Human embryonic kidney cell, HEK293-derived mouse IFN-alpha 2/IFNA2 protein
  Cys24-Glu190
• Accession #: P01573
• N-terminal Sequence: Cys24
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 19.3 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 18-22 kDa, under reducing conditions

Packaging, Storage & Formulations

• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse IFN-alpha 2/IFNA2 Protein, CF

• alpha-2a interferon
• Ifa2
• IFNA
• IFNA2
• IFNA2a
• IFNA2b
• IFNA2c
• IFNAA
• IFNalpha 2
• IFN-alpha 2
• IFN-alpha-2
• IFN-alphaA
• INFA2
• interferon alpha 2b
• interferon alpha A
• interferon alpha-2
• Interferon alpha-A
• interferon, alpha 2
• LeIF A
• MGC125764
• MGC125765

Background

Interferon-alpha 2 (IFN alpha -2) is one of 14 subtypes within the IFN-alpha class of Type I Interferons (1). The members of the IFN-alpha class, also known as alpha leukocyte interferons, encompass a group of distinct but closely related proteins which share approximately 80% amino acid (aa) sequence identity and have a similar globular structure composed of five alpha-helices (1, 3, 4). IFN-alpha class members signal through a common cell surface receptor complex composed of IFN-alpha R2 and IFN-alpha R1 subunits (3). As the first highly active IFN to be cloned and produced, IFN alpha -2 has become the prototypic IFN for academic and pharmaceutical research (2). The mature extracellular domain (ECD) of mouse IFN alpha -2 shares 60% and 83% aa sequence identity with human and rat, respectively. Murine IFN-alpha 2 can eliminate cardiac viral load and protect cardiomyocytes from injury in animals infected with coxsackievirus B3 (CVB3) (5). IFN alpha -2 derived mutants with reduced IFNR2 binding inhibited HIV replication and mutants with more IFNAR1 binding potentiated antiviral activity (6).

1. Pestka, S. (2007) J Biol Chem. 282:20047.
2. Paul, F. et al. (2015) Gene. 567(2):132.
3. Oritani, K. et al. (2001). Cytokine & Growth Factor Reviews, 12:337.
4. Pesch, V. et al. (2004). Journal of Virology, 78:8219.
5. Wang, Y.X. et al. (2007) Am J Physiol Heart Circ Physiol. 293:H69.
6. Schlaepfer, E. et al. (2019) Am Soc for Microbiology 4:e00637.

Publications for IFN-alpha 2 (10149-IF)(3)

Publications using 10149-IF

• Zhao, Q;Wang, Q;Yao, Q;Yang, Z;Li, W;Cheng, X;Wen, Y;Chen, R;Xu, J;Wang, X;Qin, D;Zhu, S;He, L;Li, N;Wu, Y;Yu, Y;Cao, X;Wang, P; Nonenzymatic lysine D-lactylation induced by glyoxalase II substrate SLG dampens inflammatory immune responses Cell research 2025-01-06 [PMID: 39757301] (Bioassay, Mouse)
• Yun, YI;Ko, JH;Ryu, JS;Kim, S;Jeon, HS;Kim, N;Kim, MK;Oh, JY; Toxicity and efficacy of type I interferons on the ocular surface: in vitro, animal, and clinical studies The ocular surface 2024-07-11 [PMID: 39002721] (In vivo assay, Mouse)
• Waugh, KA;Minter, R;Baxter, J;Chi, C;Galbraith, MD;Tuttle, KD;Eduthan, NP;Kinning, KT;Andrysik, Z;Araya, P;Dougherty, H;Dunn, LN;Ludwig, M;Schade, KA;Tracy, D;Smith, KP;Granrath, RE;Busquet, N;Khanal, S;Anderson, RD;Cox, LL;Estrada, BE;Rachubinski, AL;Lyford, HR;Britton, EC;Fantauzzo, KA;Orlicky, DJ;Matsuda, JL;Song, K;Cox, TC;Sullivan, KD;Espinosa, JM; Triplication of the interferon receptor locus contributes to hallmarks of Down syndrome in a mouse model Nature genetics 2023-06-05 [PMID: 37277650] (Bioassay, Transgenic Mouse)

Bioinformatics

• Uniprot:
  • P01573()